These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9014288)

  • 1. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer.
    Boursnell ME; Rutherford E; Hickling JK; Rollinson EA; Munro AJ; Rolley N; McLean CS; Borysiewicz LK; Vousden K; Inglis SC
    Vaccine; 1996 Nov; 14(16):1485-94. PubMed ID: 9014288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
    Kaufmann AM; Stern PL; Rankin EM; Sommer H; Nuessler V; Schneider A; Adams M; Onon TS; Bauknecht T; Wagner U; Kroon K; Hickling J; Boswell CM; Stacey SN; Kitchener HC; Gillard J; Wanders J; Roberts JS; Zwierzina H
    Clin Cancer Res; 2002 Dec; 8(12):3676-85. PubMed ID: 12473576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector.
    Gao L; Chain B; Sinclair C; Crawford L; Zhou J; Morris J; Zhu X; Stauss H
    J Gen Virol; 1994 Jan; 75 ( Pt 1)():157-64. PubMed ID: 7509369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18.
    Zhao L; Liu B; Ren J; Feng J; Pang Z; Gao J; Zhang H; Tan W; Tian H; Ruan L
    Virol J; 2011 Jun; 8():302. PubMed ID: 21672263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Construction and identification of non-replication recombinant vaccinia virus co-expressing human papillomavirus type 16 L1/L2/E6/E7 proteins].
    Huang W; Tian HW; Ren J; Fan JT; Zhao L; Bian T; Lu ZH; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):240-3. PubMed ID: 16261206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.
    Borysiewicz LK; Fiander A; Nimako M; Man S; Wilkinson GW; Westmoreland D; Evans AS; Adams M; Stacey SN; Boursnell ME; Rutherford E; Hickling JK; Inglis SC
    Lancet; 1996 Jun; 347(9014):1523-7. PubMed ID: 8684105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
    Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
    Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
    Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
    J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
    Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
    Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
    Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
    Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Construction of recombinant vaccinia virus co-expressing mutant E6 plus E7 proteins and detection of its immunogenicity and antitumor response].
    Zhi H; Han L; Ren J; Tian H; Luo W; Liang Y; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Dec; 16(4):341-4. PubMed ID: 12665900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental study of the immuno-protective activity of recombinant vaccinia virus expressing HPV58 E7].
    Luo LQ; Li J; Liu X; Zhang YH
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Feb; 25(1):43-6. PubMed ID: 12905606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
    Daemen T; Regts J; Holtrop M; Wilschut J
    Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The induction of cytotoxic T-lymphocyte precursor cells by recombinant vaccinia virus expressing human papillomavirus type 16 L1.
    Zhou JA; McIndoe A; Davies H; Sun XY; Crawford L
    Virology; 1991 Mar; 181(1):203-10. PubMed ID: 1847256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
    Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The recombinant vaccinia viruses expressing HPV type 16 wild or mutant E7 protein elicit immunity against tumor cells in mice].
    Zhi H; Han L; Ren J; Tian HW; Lao WF; Liang Y; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Sep; 15(3):222-5. PubMed ID: 11986689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Non-replicating recombinant vaccinia virus expressing HPV16 E6 and E7 proteins elicits anti-tumor immunity in mice].
    Luo WF; Han LQ; Ren J; Tian HW; Lu ZH; Zhao L; Gu SY; Ruan L
    Zhonghua Zhong Liu Za Zhi; 2003 Jul; 25(4):335-9. PubMed ID: 12921560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Construction of recombinant vaccina virus of HPV16 and its antitumor effect].
    Huang W; Tian HW; Ren J; Fan JT; Zhao L; Ruan L
    Ai Zheng; 2005 Jul; 24(7):817-22. PubMed ID: 16004807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
    Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
    Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
    Liu DW; Tsao YP; Kung JT; Ding YA; Sytwu HK; Xiao X; Chen SL
    J Virol; 2000 Mar; 74(6):2888-94. PubMed ID: 10684306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.